GlassScriptPhysician profile
Philip Bruce Meadow
NPI 1902911878
$1,850.72
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $656 · 2021: $248.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.12 | 2019-2021 | |
| Celgene Corporation | $266.37 | 2019 | |
| Ucb, INC. | $244.63 | 2019-2021 | |
| Glaxosmithkline, LLC. | $192.74 | 2019-2020 | |
| Pfizer INC. | $187.89 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $124.49 | 2019 | |
| Novo Nordisk INC | $88.38 | 2021 | |
| Antares Pharma, INC. | $85.92 | 2019-2021 | |
| Genzyme Corporation | $79.07 | 2020 | |
| Amgen INC. | $65.46 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.04 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.91 | 2021 | |
| Amarin Pharma, INC. | $21.85 | 2021 | |
| Mallinckrodt Enterprises LLC | $19.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.08 | 2021 | |
| Hikma Pharmaceuticals USA | $13.69 | 2020 | |
| Lilly USA, LLC | $11.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.22 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Meadow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.